CR20140497A - Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc - Google Patents

Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc

Info

Publication number
CR20140497A
CR20140497A CR20140497A CR20140497A CR20140497A CR 20140497 A CR20140497 A CR 20140497A CR 20140497 A CR20140497 A CR 20140497A CR 20140497 A CR20140497 A CR 20140497A CR 20140497 A CR20140497 A CR 20140497A
Authority
CR
Costa Rica
Prior art keywords
gcc
same
antibody molecules
directed therapy
provide susceptibility
Prior art date
Application number
CR20140497A
Other languages
English (en)
Inventor
Helen Frank
Alice A Mcdonald
Theresa L O'keefe
Original Assignee
Edgar Jimenez Sanchez
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140497(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgar Jimenez Sanchez, Millennium Pharm Inc filed Critical Edgar Jimenez Sanchez
Publication of CR20140497A publication Critical patent/CR20140497A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen anticuerpos y fragmentos de enlace de antígeno de anticuerpos que enlazan GCC. La invención también proporciona métodos de diagnóstico para identificar pacientes quiénes deben recibir una terapia dirigida a GCC utilizando los anticuerpos anti-GCC proporcionados en la presente.
CR20140497A 2012-04-27 2014-10-27 Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc CR20140497A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639376P 2012-04-27 2012-04-27
PCT/US2013/038542 WO2013163633A1 (en) 2012-04-27 2013-04-27 Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy

Publications (1)

Publication Number Publication Date
CR20140497A true CR20140497A (es) 2015-02-10

Family

ID=49477498

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140497A CR20140497A (es) 2012-04-27 2014-10-27 Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc

Country Status (41)

Country Link
US (3) US9000129B2 (es)
EP (1) EP2841575B1 (es)
JP (2) JP6472746B2 (es)
KR (1) KR102046435B1 (es)
CN (1) CN104395470B (es)
AR (1) AR090884A1 (es)
AU (1) AU2013251312B2 (es)
CA (1) CA2871614C (es)
CL (1) CL2014002911A1 (es)
CO (1) CO7280144A2 (es)
CR (1) CR20140497A (es)
CY (1) CY1122557T1 (es)
DK (1) DK2841575T3 (es)
DO (1) DOP2014000242A (es)
EA (1) EA034689B1 (es)
EC (1) ECSP14028523A (es)
ES (1) ES2749181T3 (es)
GE (1) GEP201706737B (es)
HR (1) HRP20191690T1 (es)
HU (1) HUE046404T2 (es)
IL (1) IL235307B (es)
LT (1) LT2841575T (es)
MA (1) MA37569B1 (es)
ME (1) ME03560B (es)
MX (1) MX362020B (es)
MY (1) MY188442A (es)
NZ (1) NZ701601A (es)
PE (1) PE20142322A1 (es)
PH (1) PH12014502399B1 (es)
PL (1) PL2841575T3 (es)
PT (1) PT2841575T (es)
RS (1) RS59370B1 (es)
SA (1) SA113340502B1 (es)
SG (1) SG11201406855TA (es)
SI (1) SI2841575T1 (es)
SM (1) SMT201900536T1 (es)
TN (1) TN2014000454A1 (es)
TW (1) TWI631137B (es)
UA (1) UA117910C2 (es)
WO (1) WO2013163633A1 (es)
ZA (1) ZA201407723B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366890B (es) 2009-10-23 2019-07-30 Millennium Pharm Inc Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
WO2015058301A1 (en) * 2013-10-21 2015-04-30 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
ES2754282T3 (es) 2014-02-14 2020-04-16 Bioventures Llc Aductos acetaminofén proteína y procedimientos de uso de los mismos
AU2015358373B2 (en) 2014-12-03 2021-05-27 Arkansas Children's Research Institute Anti-acetaminophen antibodies and acetaminophen protein adducts
US11090383B2 (en) 2015-10-01 2021-08-17 Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
US11473081B2 (en) * 2016-12-12 2022-10-18 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
CN117038018A (zh) * 2017-12-06 2023-11-10 文塔纳医疗系统公司 存储和检索数字病理学分析结果的方法
US20210330736A1 (en) * 2018-09-05 2021-10-28 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
WO2021205325A1 (en) * 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
JPWO2021246413A1 (es) * 2020-06-02 2021-12-09
CA3205007A1 (en) * 2020-12-17 2022-06-23 Parasol Biotech Ltd. Gucy2c binding molecules and uses thereof
MX2023011862A (es) * 2021-04-07 2024-01-08 Lg Chemical Ltd Polipeptido de union a gucy2c y usos del mismo.
US20260091061A1 (en) * 2022-09-28 2026-04-02 Legend Biotech Ireland Limited Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
US20240165257A1 (en) 2022-11-01 2024-05-23 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
CN121866270A (zh) * 2023-09-21 2026-04-14 南京传奇生物科技有限公司 抗gcc抗体、嵌合抗原受体及其用途
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
CN120965861B (zh) * 2025-10-22 2026-02-13 杭州博茵生物技术有限公司 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
ES2216004T3 (es) 1993-10-26 2004-10-16 Thomas Jefferson University Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas.
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
EP0951475B1 (en) 1996-05-03 2003-07-16 Thomas Jefferson University Metastatic colorectal cancer vaccine
WO1997042506A1 (en) 1996-05-03 1997-11-13 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20010039016A1 (en) 2000-03-27 2001-11-08 Waldman Scott A. Use of expression profiling for identifying molecular markers useful for diagnosis of metastatic cancer
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1489474A (zh) 2001-01-26 2004-04-14 Ӣϣ��̩��˹��˾ 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
WO2003057838A2 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (en) 2003-02-10 2010-09-08 Univ Jefferson THE USE OF GCC LIGANDS
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US8563682B2 (en) 2004-06-25 2013-10-22 Thomas Jefferson University Guanylylcyclase C ligands
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
CA2696011A1 (en) * 2007-08-10 2009-02-19 Centocor Ortho Biotech Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
MY161564A (en) 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
KR101651796B1 (ko) * 2007-11-30 2016-08-26 제넨테크, 인크. Ｖｅｇｆ 다형성 및 항―혈관신생 요법
US20110195415A1 (en) 2008-05-13 2011-08-11 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
EP2296685B1 (en) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010065293A1 (en) * 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
JP5979877B2 (ja) * 2009-02-12 2016-08-31 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト癌における変異ｒｏｓ発現
WO2010096929A1 (en) 2009-02-25 2010-09-02 Diagnocure Inc. Method for detecting metastasis of gi cancer
WO2010104035A1 (ja) * 2009-03-12 2010-09-16 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
WO2010147684A1 (en) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions for and methods of activating guanylyl cyclase c
WO2011066048A1 (en) 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
MX366890B (es) * 2009-10-23 2019-07-30 Millennium Pharm Inc Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
AU2011261161A1 (en) * 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
SG187109A1 (en) * 2010-08-13 2013-03-28 Hoffmann La Roche Neuropilin as a biomarker for bevacizumab combination therapies
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
EP2961424A4 (en) * 2013-02-28 2016-10-19 Millennium Pharm Inc ADMINISTRATION OF AN ANTI-GCC-ANTIBODY-ACTIVE CONJUGATE AND A DNA DAMAGING ACTIVE IN THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
JP2017131245A (ja) 2017-08-03
SG11201406855TA (en) 2014-11-27
CL2014002911A1 (es) 2015-01-30
SMT201900536T1 (it) 2019-11-13
EP2841575B1 (en) 2019-06-26
RS59370B1 (sr) 2019-11-29
AU2013251312B2 (en) 2018-03-22
CN104395470B (zh) 2018-02-06
CY1122557T1 (el) 2021-01-27
CA2871614A1 (en) 2013-10-31
ZA201407723B (en) 2019-01-30
PH12014502399A1 (en) 2014-12-22
EP2841575A4 (en) 2016-06-15
PE20142322A1 (es) 2015-01-25
SA113340502B1 (ar) 2015-09-17
PT2841575T (pt) 2019-10-11
MX362020B (es) 2019-01-04
EA201491977A1 (ru) 2015-04-30
CN104395470A (zh) 2015-03-04
TN2014000454A1 (en) 2016-03-30
KR102046435B1 (ko) 2019-11-19
ES2749181T3 (es) 2020-03-19
ECSP14028523A (es) 2015-09-30
US9273146B1 (en) 2016-03-01
SI2841575T1 (sl) 2019-11-29
WO2013163633A1 (en) 2013-10-31
ME03560B (me) 2020-07-20
US20160130344A1 (en) 2016-05-12
PH12014502399B1 (en) 2022-04-22
NZ701601A (en) 2016-09-30
BR112014026742A2 (pt) 2017-07-11
HRP20191690T1 (hr) 2019-12-27
CA2871614C (en) 2021-08-31
JP6472746B2 (ja) 2019-02-20
DOP2014000242A (es) 2014-11-30
IL235307B (en) 2019-07-31
MA37569B1 (fr) 2020-08-31
TW201348258A (zh) 2013-12-01
JP2015516985A (ja) 2015-06-18
IL235307A0 (en) 2014-12-31
DK2841575T3 (da) 2019-09-23
LT2841575T (lt) 2019-10-10
HUE046404T2 (hu) 2020-02-28
MY188442A (en) 2021-12-09
EA034689B1 (ru) 2020-03-06
TWI631137B (zh) 2018-08-01
EP2841575A1 (en) 2015-03-04
AR090884A1 (es) 2014-12-10
GEP201706737B (en) 2017-09-25
UA117910C2 (uk) 2018-10-25
JP6517267B2 (ja) 2019-05-22
CO7280144A2 (es) 2015-05-29
MX2014013081A (es) 2015-01-12
US20130287783A1 (en) 2013-10-31
PL2841575T3 (pl) 2020-01-31
HK1208049A1 (en) 2016-02-19
US9000129B2 (en) 2015-04-07
AU2013251312A1 (en) 2014-10-30
KR20150004882A (ko) 2015-01-13

Similar Documents

Publication Publication Date Title
DOP2014000242A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
CY1122907T1 (el) Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CY1123515T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
CY1124428T1 (el) Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
CY1122020T1 (el) Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
MX387159B (es) Moléculas basadas en il-15 y métodos para su uso.
CO7400860A2 (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
MX340295B (es) Anticuerpos monoclonales anti-c-met.
CR20130359A (es) Anticuerpos del cea
BR112013021562A2 (pt) anticorpos para cd70
CR20130499A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
UY34456A (es) Anticuerpos anti-il-36r
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
UY33850A (es) Anticuerpos anti ? cd38